Home - The Dermatology Digest

Advertisement

U.S. FDA Approves Roflumilast Cream 0.05% for AD in Kids Aged 2 to 5

October 6, 2025

Nivea Launches #SkinLikeVelour Campaign

October 3, 2025

Revance Grows Leadership Team With New Appointments

October 2, 2025

Roflumilast Topical Foam, 0.3% (Zoryve, Arcutis) in Seb Derm: Reviewing Data on Patients With Diverse Skin Types

October 2, 2025

Done Deal: LEO Pharma Closes Deal for BI’s Spesolimab (Spevigo)

October 2, 2025

Targeting IL-22 in AD: A Q&A About LEO Pharma’s Temtokibart With Michael Ardern-Jones

October 1, 2025

Advertisement

2025 Maui Dermatology Abstract Supplement

Burning Truths: Exposing Sunscreen Misconceptions for Better Protection

Beyond the Headlines: Elevating Care for HS Patients, Part 1

Beyond the Headlines: Recommendations for Appropriate Utilization of Systemic Therapies in AD

Beyond the Headlines: Diagnosing and Treating Chronic Hives

Expert Perspectives: Itching for Relief

Advertisement

Latest Issue

Latest Supplements

Upcoming Conferences

Advertisement

Advertisement

Digital Edition Archive